Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to equity ratio high or low?
The debt to equity ratio of 0.02 is 108% above its 2-year average of -0.28, near the high end of its 2-year range (-1.33–0.02).
As of the fiscal period ended Tuesday, June 30, 2026. 104.23% above its 12-month average of -0.55.
Reported quarterly debt to equity ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 0.02.
DEBT TO EQUITY RATIO
0.02
DEBT TO EQUITY RATIO AVG TTM
-0.55
DEBT TO EQUITY RATIO AVG 3Y
N/A
DEBT TO EQUITY RATIO AVG 5Y
N/A
DEBT TO EQUITY RATIO AVG 10Y
N/A
DEBT TO EQUITY RATIO AVG 15Y
N/A
DEBT TO EQUITY RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
+104.23%
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.11
median of 697 covered companies
CURRENT VS SECTOR MEDIAN
-78.67%
vs the sector median at left
Lakewood-Amedex Biotherapeutics, Inc.
Market Cap
$1.46M
Debt to Equity Ratio
0.02
TTM Avg
-0.55
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.48M
Debt to Equity Ratio
0.83
TTM Avg
0.17
3Y Avg
0.16
5Y Avg
0.13
Market Cap
$1.43M
Debt to Equity Ratio
0.24
TTM Avg
0.63
3Y Avg
2.77
5Y Avg
1.75
Market Cap
$1.38M
Debt to Equity Ratio
0.01
TTM Avg
0.02
3Y Avg
0.01
5Y Avg
0.01
| NAME | MARKET CAP | DEBT TO EQUITY RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Lakewood-Amedex Biotherapeutics, Inc. (LABT) | $1.46M | 0.02 | -0.55 | N/A | N/A |
| Curis, Inc. (CRIS)vs › | $1.47M | 0.22 | 0.30 | 0.17 | 0.13 |
| PMGC Holdings Inc. (ELAB)vs › | $1.48M | 0.83 | 0.17 | 0.16 | 0.13 |
| NEXGEL, Inc. (NXGL)vs › | $1.43M | 1.51 | 0.59 | 0.51 | 3.40 |
| INVO Fertility, Inc. (IVF)vs › | $1.43M | 0.24 | 0.63 | 2.77 | 1.75 |
| Artelo Biosciences, Inc. (ARTL)vs › | $1.38M | 0.01 | 0.02 | 0.01 | 0.01 |
| Genprex, Inc. (GNPX)vs › | $1.33M | 0.00 | 0.00 | 0.00 | 0.00 |
| NewcelX Ltd. (NCEL)vs › | $1.32M | 0.06 | 0.03 | 0.02 | 0.01 |
| Silo Pharma, Inc. (SILO)vs › | $1.64M | 0.00 | 0.00 | 0.00 | 0.00 |
| Jupiter Neurosciences, Inc. (JUNS)vs › | $1.24M | N/A | 0.05 | 0.05 | 0.05 |
Debt/Equity
0.02
Current Ratio
7.70
Debt to Equity measures financial leverage by comparing total debt to shareholders' equity.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO EQUITY RATIO |
|---|---|
| 2026-06-30 | 0.02 |
| 2026-03-31 | -0.62 |
| 2025-12-31 | -0.85 |
| 2025-09-30 | -1.33 |
| 2025-06-30 | 0.00 |
| 2025-03-31 | 0.00 |
| 2024-12-31 | 0.00 |
| 2024-09-30 | 0.00 |
| 2024-06-30 | 0.00 |
| 2024-03-31 | 0.00 |
